The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Full approval will depend on verification of clinical benefit in a confirmatory trial
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea
The formulation is backed by over 80 clinical trials and 200 scientific publications
Subscribe To Our Newsletter & Stay Updated
